[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunogenicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunogenicity":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100612694","phase-4-a-trial-to-establish-non-inferiority-of-immunogenicity-of-a-single-dose-of-cervavac-quadrivalent-hpv-vaccine-compared-to-the-gardasil-quadrivalent-vaccine-among-girls-and-boys-aged-9-to-14-years-and-in-girlswomen-aged-15-to-20-years-in-zambia-100612694",false,"NCT07256912","A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","CervALONE","Inclusion Criteria:\n\n1. Girl\u002Fwoman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.\n2. Participant willing to sign a written informed consent (for participants 18 years of age and above).\n3. Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).\n4. Participant or parent (s) willing to comply with all study requirements.\n5. Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.\n\nExclusion Criteria:\n\n1. Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.\n2. Participant has a known history of prior vaccination with any HPV vaccine.\n3. Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)\n4. Participant currently enrolled in any other clinical studies of investigational products.\n5. Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.\n6. Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.\n7. Participant has a history of any allergic diseases or severe allergic reaction to any agent\u002Fvaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).\n8. Participant has had an acute illness (moderate or severe) and\u002For fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.\n9. Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.\n10. Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.\n11. Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of \\>0.5 mg\u002Fkg\u002Fday), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.\n12. Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.\n13. Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.\n14. Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.\n15. Participant has history of any cancer, organ transplant or any other immune system disease.\n16. Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures",true,"ALL","9 Years","20 Years",{"count":22,"type":23},1266,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls\u002Fwomen aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls\u002Fwomen in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.",[29,30,31,32,33,34],"Vaccine Effectiveness","HPV Vaccination","Single Dose","Immunogenicity","Cervical Cancer Prevention","Quadrivalent HPV Vaccine",[36,37,38,39,40],"HPV","VACCINE","SINGLE DOSE","cervical cancer prevention","Quadrivalent HPV vaccine","NOT_YET_RECRUITING","2026-03-23",{"date":44,"type":45},"2026-03-24","ACTUAL",{"date":47,"type":23},"2026-04-01",{"date":49,"type":23},"2029-01-15",{"name":51,"class":52},"International Agency for Research on Cancer","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100630298","phase-3-influenza-vaccination-strategy-for-patients-with-hematologic-malignancy-100630298","NCT07485855","Influenza Vaccination Strategy for Patients With Hematologic Malignancy","Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies","(HEM-FLU)","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Confirmed diagnosis of hematologic malignancy, including:\n\nnon-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders\n\nExclusion Criteria:\n\n* Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)\n* Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures\n* Known hypersensitivity to influenza vaccine components\n* Influenza vaccination within the preceding 6 months\n* Any other condition deemed clinically inappropriate for study participation at investigator discretion","19 Years",{"count":64,"type":23},60,[66],"PHASE3","This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population",[69,70,32],"Hematologic Neoplasms","Influenza","RECRUITING","2026-03-20",{"date":44,"type":45},{"date":75,"type":45},"2025-12-04",{"date":77,"type":23},"2028-04-30",{"name":79,"class":52},"Asan Medical Center",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":53},"100625964","phase-1-safety-and-immunogenicity-of-pro-169-in-patients-with-diabetic-macular-edema-100625964","NCT07429474","Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema","Phase I Clinical Trial to Evaluate Safety by Determining Immunogenicity Following Unilateral Intravitreal Administration of PRO-169 in Patients With Diabetic Macular Edema","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of type 1 or type 2 diabetes.\n3. Ability to provide signed informed consent.\n4. Ability and willingness to comply with scheduled visits, treatment plan, and other study procedures.\n5. All subjects (male and female) who are biologically capable of having children must agree and commit to using a barrier or hormonal contraceptive method (by any route of administration) for the entire duration of the study and for 3 months after the last intravitreal injection.\n6. Female subjects who are biologically capable of having children must have a negative urine pregnancy test at the screening visit.\n7. Best-corrected visual acuity (BCVA) according to the ETDRS chart from 24 to 78 letters (approximate Snellen equivalent of 20\u002F32 to 20\u002F320).\n8. Diabetic macular edema with central involvement evidenced by spectral domain optical coherence tomography (central macular thickness criterion \\> 300 µm for men and \\> 290 µm for women) within 8 days prior to inclusion. All measurements taken on a subject must be taken with an instrument of the same make and model throughout the study.\n9. Meet characteristics that allow for adequate fundus examination (media transparency, adequate pupil dilation).\n10. Glycosylated hemoglobin \\\u003C 12% from a result no older than 3 months.\n\nExclusion Criteria:\n\n1. Chronic kidney disease with renal failure (glomerular filtration rate \\[eGFR\\] \\\u003C15 mL\u002Fmin\u002F1.73 m2) requiring dialysis or transplantation; according to the 2020 Clinical Practice Guideline for the Management of Diabetes in Chronic Kidney Disease from the Kidney Disease Improving Global Outcomes (KDIGO) organization.\n2. Active proliferative diabetic retinopathy in the study eye, including rubeosis iridis, vitreous hemorrhage, or tractional retinal detachment visible during the screening visit.\n3. Individuals who have required initiation of insulin therapy for glycemic control within 4 months prior to the screening visit.\n4. Previous participation in clinical studies with investigational products, ocular or systemic (at least 30 days must have elapsed between the end of participation in a previous trial and inclusion in this study).\n5. Known hypersensitivity or allergy to bevacizumab or any ingredient in the investigational product.\n6. Poorly controlled blood pressure (average of 3 blood pressure readings in a seated position with ≥160 mmHg systolic or ≥100 mmHg diastolic) at the screening visit.\n7. Myocardial infarction or other cardiovascular event (cerebrovascular disease, transient cerebral ischemia, or hospitalization for heart failure) during the 4 months prior to the screening visit, or subjects with active myocardial ischemia.\n8. Systemic treatment with VEGF-related drugs within 4 months prior to the screening visit.\n9. History of any rheumatological or collagen disease of autoimmune origin related to inflammatory processes such as: systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, Behçet's disease, dermatomyositis, among others.\n10. History of any disease that causes immunosuppression or immunodepression, except diabetes mellitus.\n11. Concomitant use of immunosuppressive agents, immunotherapy, or monoclonal antibodies by any route of administration (other than intravitreal) in the 2 years prior to the screening visit or during the study period.\n12. Subjects who have received intravitreal anti-VEGF treatment (aflibercept, ranibizumab, bevacizumab, faricimab, brolucizumab) in the study eye within 4 months prior to the screening visit.\n13. Use of intraocular or periocular corticosteroids in the study eye within 4 months prior to the screening visit, or use of intravitreal corticosteroid implants at any time.\n14. Use of anticoagulants or antiplatelet agents by any route of administration within 10 days prior to the screening visit or during the study period.\n15. Women of childbearing potential who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n16. Allergy to fluorescein (topical or intravenous) or to anesthetic medications used during the injection procedure.\n17. Subjects with non-diabetic macular edema.\n18. Lens opacities that, according to the LOCS III (Lens Opacities Classification System) classification, exceed one or more of the following criteria: nuclear component \\> NO3C3 (opalescence\u002Fcolor), cortical component \\> C2, and posterior subcapsular component \\> P1.\n19. History of eye surgery (cataract extraction, any intraocular surgery, aphakia, etc.) or panretinal photocoagulation within 3 months prior to the screening visit or planned within the study period.\n20. Intraocular pressure greater than 21 mmHg in the selected eye, measured by Goldmann tonometry at the screening visit.\n21. Presence of macular ischemia or significant perifoveal capillary loss (increase in foveal avascular zone greater than 350 µm) demonstrated by fluorescein retinal angiography (during the screening visit or in a study performed within 4 months prior to the screening visit).\n22. History of YAG capsulotomy in the study eye within 30 days prior to the screening visit.\n23. Evidence of external eye infections, intraocular inflammation, or significant ocular surface disease in either eye within 30 days prior to the screening visit.\n24. History of uveitis in the study eye.\n25. History of retinal detachment, vitrectomy, any type of filtering surgery, corneal transplant, or corneal dystrophy in the selected eye.\n26. Advanced glaucoma or optic neuropathy in the selected eye.\n27. Having only one functional eye (best corrected visual acuity of finger counting or less in the eye with the worst vision).\n28. Having previously participated in this same study.\n29. Being or having an immediate family member (e.g., parent\u002Flegal guardian or sibling) who is part of the research site staff or sponsor.\n30. Subjects with conditions that make it difficult or impossible to draw blood, such as veins that are difficult to see or feel, venous thrombosis in the area where the sample is taken, severe edema, or any other criteria determined by the personnel responsible for performing this procedure.\n31. Difficulty interpreting the optotypes on the ETDRS chart.","18 Years",{"count":64,"type":23},[90],"PHASE1","Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.",[32,93],"Anti-drug Antibodies (ADAs)","2026-03-11",{"date":96,"type":45},"2026-03-13",{"date":98,"type":23},"2026-03-01",{"date":100,"type":23},"2026-12-15",{"name":102,"class":103},"Laboratorios Sophia S.A de C.V.","INDUSTRY"]